Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis.

ABSTRACT:

Objective

We assessed CSF levels of the light chain subunit of neurofilaments (NfL) at baseline and after fingolimod therapy or placebo in patients with relapsing-remitting multiple sclerosis (RRMS). Changes in NfL levels were also correlated with relapse and MRI outcomes.

Methods

CSF samples were available, at baseline and 12 months after treatment initiation, from a subset of 36 patients with RRMS (fingolimod 0.5 mg: n = 9; fingolimod 1.25 mg: n = 15; placebo: n = 12) participating in the 2-year, phase 3 Fingolimod (FTY720) Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) study. NfL levels were determined in a blinded fashion using a commercial ELISA kit.

Results

Median NfL levels did not differ between treatment groups at baseline

SUBMITTER: Kuhle J 

PROVIDER: S-EPMC4409586 | biostudies-literature | 2015 Apr

REPOSITORIES: biostudies-literature